TCP Venture Capital

TCP Venture Capital is an early-stage technology-focused firm based in Baltimore that invests in software and healthcare technology applications. The healthcare focus is on health IT and software platforms rather than devices or therapeutics. AI is not the explicit thesis, though software-led companies in this category increasingly embed AI in their workflows. For founders, TCP fits the profile of a regional, sector-spanning early-stage fund where the partner relationship and Mid-Atlantic ecosystem ties matter more than deep healthcare specialization.

The firm writes $250k to $1M checks at Seed and Series A. That sizing makes TCP a candidate for first institutional money or a meaningful follow-on participant in small early rounds, but unlikely to lead larger priced rounds without syndicate partners.

Founders should approach TCP Venture Capital when they are building a health IT or healthcare software product, particularly one with a Mid-Atlantic footprint or commercial traction in the region. Devices, biotech, and care-delivery services are out of scope. Because the check size is modest, expect TCP to participate in syndicated rounds rather than lead alone — founders should plan their syndicate accordingly. The firm’s broader technology portfolio means partners will evaluate healthcare deals through a software-business lens: gross margins, retention, and scalability of the go-to-market. Bring a clear ARR or pipeline story rather than a clinical-evidence narrative.